Abstracts tagged "rheumatoid arthritis (RA) and tofacitinib"

Abstract Number: 1643 • 2015 ACR/ARHP Annual Meeting
Modified-Release Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared with Immediate-Release Tofacitinib and Impact of Food
Manisha Lamba¹, Rong Wang¹, Tracey Fletcher², Christine Alvey¹, Joseph Kushner¹ and Thomas Stock², ¹Pfizer Inc, Groton, CT, ²Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A modified-release (MR) formulation has been designed to enable once daily (QD)…
Abstract Number: 2706 • 2015 ACR/ARHP Annual Meeting
3D Location of Erosions in an Early Rheumatoid Arthritis Population: An MRI Study Using Statistical Shape Models with Implications for Pathogenesis
Michael A. Bowes¹, Gwenael Guillard¹, Z. Xie², Bethanie Wilkinson² and Philip G. Conaghan³, ¹Imorphics, Manchester, United Kingdom, ²Pfizer Inc, Groton, CT, ³University of Leeds & NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom
Background/Purpose: Concepts of erosion pathogenesis in rheumatoid arthritis (RA) have been based on radiographs, although MR images are much better able to visualise erosions. Statistical…
Abstract Number: 2741 • 2015 ACR/ARHP Annual Meeting
An Analysis of the Efficacy of Tofacitinib Monotherapy in MTX-Naïve Patients with Early RA Compared with Patients with Established RA
Roy Fleischmann¹, T. W. J. Huizinga², Arthur Kavanaugh³, Bethanie Wilkinson⁴, Kenneth Kwok⁵, Ryan DeMasi⁵ and Ronald F. van Vollenhoven⁶, ¹Metroplex Clinical Research Center, Dallas, TX, ²Leiden University Medical Center, Leiden, Netherlands, ³University of California, San Diego School of Medicine, LaJolla, CA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. In a Phase 3 study (ORAL Start; NCT01039688), tofacitinib monotherapy in MTX-naïve…
Abstract Number: 2755 • 2015 ACR/ARHP Annual Meeting
Evaluating Pharmacokinetic Predictors of Tofacitinib Clinical Response in Rheumatoid Arthritis
Manisha Lamba¹, Daniel E. Furst², Ara Dikranian³, Martin Dowty¹, Matthew M Hutmacher⁴, Daniela Conrado¹, Thomas Stock⁵, Chudy Nduaka⁵ and Sriram Krishnaswami¹, ¹Pfizer Inc, Groton, CT, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³San Diego Arthritis Medical Clinic, San Diego, CA, ⁴Ann Arbor Pharmacometrics Group, Ann Arbor, MI, ⁵Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A modified-release (MR) formulation to provide a once-daily (QD) dosing alternative to…
Abstract Number: 2910 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice
Keisuke Nishimura¹, Jun Saegusa¹, Fumichika Matsuki², Kengo Akashi¹, Goichi Kageyama¹ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that are characterized by the co-expression of Gr1 and CD11b in mice. MDSCs suppress…
Abstract Number: 1908 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014
A. Marren¹, Y. Chen¹, D. Frazier² and J. Geier³, ¹Pfizer Inc, Collegeville, PA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Its effect in pregnant women is of interest, as tofacitinib…
Abstract Number: 486 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Improves Arterial Stiffness Despite up-Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study
Kensuke Kume¹, Kanzo Amano², Susumu Yamada², Toshikatsu Kanazawa³, Hiroshi Komori⁴, Kazuhiko Hatta⁵, Kuniki Amano⁶ and Noriko Kuwaba⁷, ¹20-16 Higashi Kannon, Nishi Ward, hiroshima clinic, Hiroshima, Japan, ²Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴internal medicine, hiroshima clinic, hiroshima, Japan, ⁵Rheumatology, Hatta Clinic, Kure, Japan, ⁶Rheumatology, Sky Clinic, Hiroshima, Japan, ⁷Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased cardiovascular (CV) risk. We should have strategies for primary cardiovascularprevention in RA. Tofacitinib (Tofa) could possibly…
Abstract Number: L9 • 2013 ACR/ARHP Annual Meeting
Tofacitinib Monotherapy Versus Methotrexate in Methotrexate-Naïve Patients with Rheumatoid Arthritis: Radiographic, Clinical and Functional Comparison
Roy Fleischmann¹, E. B. Lee², S Hall³, B. E. Wilkinson⁴, John D. Bradley⁵, D. Gruben⁴, T. Koncz⁶, S. Krishnaswami⁷, G. Wallenstein⁶, S. H. Zwillich⁴ and R.F. van Vollenhoven⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Seoul National University, Seoul, South Korea, ³Cabrini Health and Monash University, Melbourne, Australia, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc., Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁸The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of RA. This Phase 3, 24-mo study (ORAL Start; NCT01039688) compared efficacy, including inhibition…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].